(Reuters) There are no approved vaccines and only one drug in the United States for respiratory syncytial virus (RSV), a common respiratory virus that usually causes mild, cold-like symptoms but can also lead to serious illness and hospitalization. Sanofi and AstraZeneca drug nirsevimab recently became the second to get Europe’s approval to prevent RSV infections in infants, after Swedish drugmaker Orphan Biovitrum’s Synagis. Nirsevimab does not have U.S. approval yet.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.